Spots Global Cancer Trial Database for Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Official Title: A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells

Study ID: NCT00020670

Conditions

Leukemia

Interventions

CD 40

Study Description

Brief Summary: The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these patients, novel therapeutic approaches such as immunotherapy are needed. In this clinical trial, investigators evaluate whether it is feasible to make a vaccine from leukemia cells and whether this vaccine enables direct immunity against cancer cells in patients.

Detailed Description: OBJECTIVES Primary * To determine feasibility of generating a cellular vaccine composed of CD40-activated autologous ALL cells * To determine feasibility of vaccine administration according to the proposed schedule * To determine toxicity of vaccination with CD40-activated autologous ALL cells Secondary * To assess ALL-specific immunity following vaccination * To assess the generation of immunity to control antigens * To develop preliminary information on effect vaccination on tumor response